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High-dose regimes containing etoposide, carboplatin and an oxazaphospharine can salvage 30–40% of patients with relapsed or
refractory male germ cell tumours (GCTs). The additional benefit of paclitaxel in such high-dose therapy has not been tested.
Between March 1995 and November 2002, 36 male GCT patients were treated with Carbop-EC-T (paclitaxel 75mgm
 2, etoposide
450mgm
 2, carboplatin AUC 10 on days  7,  5 and  3 and cyclophosphamide 60mgkg
 1 on days  5 and  3) followed by
peripheral blood stem cell infusion (day 0). The 1-year overall survival rate for all patients is 67% (median follow-up 29 months). For
the 24 patients with cisplatin-sensitive disease, the 1-year overall and event-free survivals are 88 and 64%, respectively. For those with
cisplatin refractory or absolutely refractory disease, the 1-year overall survival is 25%. In all, 12 patients relapsed at a median duration
of 5 months, 11 of whom have died. There were also six treatment-related deaths, five associated with pneumonitis. Pulmonary
toxicity has been reported with paclitaxel in other high-dose regimes. Since altering our protocol so that paclitaxel is infused over
24h with steroid prophylaxis, only one of 18 patients (13 testicular GCTs and five other tumour types) has had a treatment-related
death. Our results suggest that Carbop-EC-T may enable a greater proportion of patients with relapsed and refractory GCTs to enter
long-term remission.
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Germ cell tumours (GCTs) are extremely chemosensitive and up to
80% of patients with metastatic disease are cured with conven-
tional cisplatin-based chemotherapy (Bower et al, 1997; Toner et al,
2001). However, for those patients with either relapsed, cisplatin-
refractory disease or disease that is classified as IGCCCG poor
prognosis (Mead et al, 1997), the outcome is much less favourable.
For relapsed disease, conventional dose salvage regimes, such as
VeIP (vinblastine, ifosfamide and cisplatin), can produce response
rates of greater than 50%, but long-term cures are relatively rare
(Loehrer et al, 1998). The first reports of the use of high-dose
chemotherapy with peripheral blood stem cell support in heavily
pretreated relapsed GCTs appeared in the late 1980s, showing long-
term survival rates of 15–20% (Nichols et al, 1989). With
improved patient selection and management, high-dose therapy
with three drug regimes (usually etoposide, carboplatin and an
oxazaphospharine) produced long-term survival rates of 30–40%
(Beyer et al, 1996; Rick et al, 1999). Subsequently, high-dose
treatment has been introduced increasingly early in the manage-
ment of GCTs: as initial salvage, long-term survival rates of over
50% can be achieved (Bhatia et al, 2000) and as first-line treatment
in those with poor prognosis disease, there is data from matched
pair analysis to suggest a survival advantage for those treated with
high-dose therapy compared to standard dose (Bokemeyer et al,
1999).
We have previously reported the outcome of 31 heavily
pretreated patients who received high-dose carboplatin, etoposide
and cyclophosphamide (Carbop-EC) followed by peripheral
blood stem cell rescue (Lyttelton et al, 1998). There was one
treatment-related death and the probability of event-free and
overall survival at 3 years was 30 and 42%, respectively. In the
patients with cisplatin-responsive relapses, overall survival was
60% at 3 years, but in patients with cisplatin-refractory disease,
there were no survivors beyond 36 months. In an attempt to
increase the rate of long-term survival, we introduced paclitaxel to
this regime as it has activity in GCTs, both as a single agent
(Motzer et al, 1994) and in combination (de Wit et al, 1999). Here,
we report the outcome of the first 36 patients with relapsed or
refractory testicular GCTs treated with this new regime, which we
have named Carbop-EC-T.
PATIENTS AND METHODS
Patients
Between March 1995 and November 2002, we treated 36 patients
with relapsed or refractory testicular GCTs. The details of
the patients are listed in Table 1. The protocol was subjected to
the appropriate local institutional review and all patients gave
written informed consent prior to treatment. The median age
at the time of treatment was 37 years (range 19–69 years)
and patients had received a median of 3 (range 2–6) cisplatin-
containing chemotherapy regimes prior to high dose.
The histology of the tumours was seminoma in 10 out of
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l36 (28%) and nonseminomatous germ cell tumour (NSGCT) in the
remaining 26 patients (72%). At initial presentation, 26 out of 36
(72%) patients were classified as IGCCCG good prognosis, five out
of 36 (14%) intermediate prognosis and five out of 36 (14%) poor
prognosis. For seven out of 36 patients (19%), high-dose
chemotherapy was given to intensify first salvage treatment, while
27 of the 36 (75%) had received more than one salvage regime
prior to high-dose therapy. For the two remaining patients, high-
dose therapy was given as intensification of first-line treatment
after no response better than stable disease (SD) could be achieved
with three consecutive standard dose regimes. Two patients had
previously received Carbop-EC high-dose treatment and had
relapsed after 12 and 24 months. Two patients received Carbop-
EC-T twice; the first having SD after three standard dose regimes,
but achieving a complete marker response to the first dose of
Carbop-EC-T and so the second dose was given as consolidation.
The second patient relapsed 6 months after the first Carbop-EC-T,
but still had cisplatin-responsive disease and had sufficient
peripheral blood stem cells stored to permit a second high-dose
treatment.
By the criteria of Beyer et al. (1996) (see definitions below),
24 patients (67%) had cisplatin-sensitive disease, seven (19%)
cisplatin-refractory disease and four (11%) were defined
as absolutely refractory. Using the prognostic risk categories
(Beyer et al, 1996) (see definitions below), 20 patients were
good risk, 12 were intermediate and four were poor risk. In
the majority of patients (33 out of 36), peripheral blood stem
cells were harvested using a single bolus regime of high-dose
etoposide (1.6gm
 2) followed by 12 daily injections of granulocyte
colony-stimulating factor prior to leukapheresis (Kanfer et al,
1998). Prior to treatment, all patients had assessment of
left ventricular function (trans-thoracic echocardiography and/or
MUGA scanning), renal function (as measured by 24h
urinary creatinine clearance or EDTA clearance) and lung function
(spirometry, lung volumes and gas transfer). The median
estimated glomerular filtration rate was 67mlmin
 1 (range
30–146). The median LV ejection fraction was 58%
(range 30–78%), while the median forced expiratory volume in
1s (FEV1) was 87% of predicted (range 47–122%) and the median
carbon monoxide transfer (KCO) was 96% predicted (range
68–142%).
Chemotherapy
The Carbop-EC-T regime is outlined in Table 2. Prior to receiving
Carbop-EC-T, patients received conventional dose induction
chemotherapy: 24 out of 36 patients received three cycles
of TE/TP (paclitaxel 90mgm
 2 and etoposide 150mgm
 2 on
day 1, paclitaxel 90mgm
 2 and cisplatin 60mgm
 2 on day 14,
with treatment recommencing on day 29). Two patients, with
EDTA clearances of under 40mlmin
 1, received TE/TCarbo,
in which cisplatin was substituted with carboplatin at a dose of
area under curve (AUC) 5mgmlmin
 1 according to the Calvert
formula (dose¼AUC (GFRþ25) mg) (Calvert et al, 1989).
The remaining patients received a variety of induction regimes:
POMB/ACE (Bower et al, 1997) (four patients), 5 day BEP (two
patients), VeIP (two patients), EP (etoposide 500mgm
 2 and
cisplatin 75mgm
 2 every 14 days: two patients) and gemcitabine
(1gm
 2), carboplatin (AUC 5) paclitaxel (135mgm
 2: one
patient).
Carbop-EC-T is a derivative of the regime that we have
described previously (Lyttelton et al, 1998), itself a modification
of a regime used at the Memorial Sloan-Kettering Cancer Center.
It consists of etoposide 450mgm
 2 on days  7,  5 and  3 (total
1350mgm
 2), paclitaxel 75mgm
 2 on days  7,  5 and  3
(total 225mgm
 2), carboplatin AUC 10 on days  7,  5 and
 3 (total dose AUC 30) and cyclophosphamide 60mgkg
 1 on
Table 1 Patient characteristics
Carbop-EC-T
N¼36
Median age 37.4 years (range 19–69)
Median follow-up 29 months (range 4–89)
Disease
Teratoma 26
Seminoma 10
Median previous chemotherapy regimes 3 (2–6)
Sensitivity to cisplatin (Beyer’s criteria)
Sensitive 24
Refractory 7
Absolutely refractory 5
Prognostic risk score
Good (score 0) 20
Intermediate (score 1–2) 12
Poor (score 42) 4
IGCCCG classification
Good 26
Intermediate 5
Poor 5
Median estimated GFR 67mlmin
 1 (range 30–146)
Left ventricular ejection fraction 58% (range 30–78%)
Lung function tests
FEV1 87% predicted (range 47–122%)
KCO 96% predicted (range 68–142%)
Table 2 The Carbop-EC-T regime
Day-7
Paclitaxel 75mgm
 2 over 3h (now 24h) with
dexamethasone 20mg 12 and 6h prior
Etoposide 450mgm
 2 over 2h
Carboplatin AUC 10 (¼10 (GFR+25) mg) over 1h
Dexamethasone 20mg 12 and 6h prior to paclitaxel
Day-5
Paclitaxel 75mgm
 2 over 3h (now 24h) with
dexamethasone 20mg 12 and 6h prior
Etoposide 450mgm
 2 over 2h
Carboplatin AUC 10 over 1h
Cyclophosphamide 60mgkg
 1 over 1h+MESNA 120mgkg
 1
Day-3
Paclitaxel 75mgm
 2 over 3h (now 24h) with
dexamethasone 20mg 12 and 6h prior
Etoposide 450mgm
 2 over 2h
Carboplatin AUC 10 over 1h
Cyclophosphamide 60mgkg
 1 over 1h+MESNA 120mgkg
 1
Day 0
Reinfuse peripheral
blood stem cells
2 10
6 CD34+ve cells/kg
Days 0–14 (last 13
patients only)
Prednisolone 30mgb.d.
AUC¼area under curve.
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ldays  5 and  3 (total dose 120mgkg
 1). Mesna was given to all
patients to prevent urological toxicity. All patients received
granisetron (3mg i.v. per day), dexamethasone (4mg b.d.)
and domperidone (20mg t.d.s.) on days  7 to 0 as antiemetic
prophylaxis. In light of the observed toxicity (vide infra), the
final 13 patients received each dose of paclitaxel over 24h
rather than 3h with steroid prophylaxis of prednisolone 30mg
twice daily for 14 days commencing on day 0. All patients received
3 months of prophylactic antibiotics with ciprofloxacin, flucona-
zole and aciclovir. No additional prophylaxis was given to the 13
patients who received prednisolone. Pulmonary toxicity was
treated with supportive care (oxygen and assisted ventilation as
necessary).
Definitions
Tumour sensitivity to cisplatin was classified according to the
response to the last conventional dose induction chemotherapy
regime prior to high-dose treatment. Tumours were defined as
cisplatin sensitive if a response better than SD was achieved with
no evidence of progression within 4 weeks. Cisplatin-refractory
disease was defined when SD or better was achieved, but there was
progression within 4 weeks, while absolutely refractory tumours
progressed during the last cisplatin-based chemotherapy treatment
(Rick et al, 1998).
In the prognostic scoring system (Beyer et al, 1996), having
progressive disease (PD) prior to high-dose treatment, a mediast-
inal primary tumour and having refractory disease prior to high-
dose treatment each gave a score of 1, while having absolutely
refractory disease and an hCG value of 41000IUl
 1 prior to high-
dose treatment each gave a score of 2. Patients who scored 0
overall were classified as good prognostic risk, those with score 1–
2 were deemed intermediate risk and those with a score 42 were
classified as poor risk. For the two patients who received Carbop-
EC-T twice, the Beyer score was calculated at their first treatment.
Statistical analyses
The probabilities of event-free and overall survival were calculated
according to the technique of Kaplan and Meier (1958)
and compared using log-rank analysis. All dates were calculated
from day 0, the day of stem cell reinfusion. An event was defined
as disease progression, disease relapse or death from any
cause, which ever came first. Patients with no events were
censored as of 1 November 2003. Statistical calculations
were performed using Prism 3.0 software (GraphPad Software,
San Diego, CA USA).
RESULTS
With a median duration of follow- up of 29 months (range
4–89 months), the median event-free survival for all 36 patients is
12.1 months with a probability of event-free survival of 51 and 48%
at 1 and 2 years, respectively. The median overall survival is 32.2
months and the probability of overall survival is 67 and 58%
at 1 and 2 years, respectively (Figure 1). As has been reported
previously, patients with cisplatin-sensitive disease do consider-
ably better than those with refractory disease and this is
borne out in our data (Figure 2a and b). Owing to the small
numbers involved, patients with cisplatin-refractory and
absolutely refractory disease have been analysed together. The
median event-free and median overall survivals have not yet
been reached for the 24 patients with cisplatin-sensitive disease,
but the probability of event-free survival at both 12 and 24 months
is 64% (Figure 2a) and, for overall survival, these probabilities
are 88 and 74% (Figure 2b), respectively. By contrast, the median
event-free and overall survival for the 12 patients with cisplatin-
refractory disease is 2 months (comparison with cisplatin sensitive;
P¼0.0007) and 6 months (comparison with cisplatin sensitive;
P¼0.0003), respectively. However, two patients with refractory or
absolutely refractory disease have survived without relapse for
over 48 months. When analysed by tumour type, there is a
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Figure 1 Estimates of event-free and overall survival for all 36 patients
treated with Carbop-EC-T.
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Figure 2 Estimates of event-free (A) and overall (B) survival for patients
stratified according to cisplatin sensitivity by the criteria of Beyer et al.
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lnonsignificant trend for improved prognosis for patients with
seminoma. The probability of overall survival at 24 months is 73%
for the 10 patients with seminoma compared to 51% for the 26
patients with NSGCT, but the numbers are too small to permit firm
conclusions from this comparison.
We have also analysed patients according to the prognostic risk
scores devised by Beyer et al. (1996) (Figure 3). As expected, the
patients who fall into the good prognostic group (score 0) have the
best survival data; 12 month event-free survival 75%, 12 month
overall survival 95%. However, even for those who fall into the
intermediate group (score 1–2), outcomes are significantly worse:
median event-free survival 3.5 months (comparison with good
prognosis; P¼0.004) and median overall survival 8.9 months
(comparison with good prognosis; P¼0.004). For the poor
prognosis group, the outcomes are worse still: median event-free
and overall survivals are both 2.6 months (comparison with good
prognosis; Po0.0001 for both analyses) with no patient surviving
for greater than 12 months.
Following Carbop-EC-T, 12 patients have relapsed at a median
duration of 5 months (range 2–12), of whom 11 have subsequently
died. Overall, there have been 18 deaths. In addition to the 11
patients with relapsed disease, one patient died of a secondary
Non-Hodgkin’s lymphoma that developed 31 months following
Carbop-EC-T and which was refractory to treatment. There have
been six treatment-related deaths (17%), of which five were
associated with pneumonitis. Pulmonary toxicity has been
reported to complicate other regimes that contain taxanes both
at high dose (Damon et al, 1997) and at conventional doses
(Dunsford et al, 1999; Wang et al, 2001). In an attempt to reduce
this pulmonary toxicity, we altered the paclitaxel regime in
December 2000 so that patients received each dose of paclitaxel
as a 24h infusion rather than over 3h (Zimmerman et al, 1998)
and also received prednisolone 30mg twice daily for 2 weeks
(Thomas et al, 2000). A total of 13 patients have now received
Carbop-EC-T in this way and there has been one treatment-related
death (8%). We have also used the 24h paclitaxel Carbop-EC-T
regime to treat two patients with relapsed ovarian GCTs and three
patients with relapsed gestational choriocarcinoma, none of whom
has had a treatment-related death. Thus, overall there has been
only one treatment-related death in 18 patients (5.5%) treated with
the modified regime.
The characteristics of the six patients who had treatment-related
deaths showed no significant difference compared to the whole
cohort for median age (37.4 vs 37 years), glomerular filtration rate
(67 vs 75mlmin
 1) or number of previous chemotherapy regimes
(3 vs 3) (see Table 1). There was also no significant difference in
the number of patients with IGCCCG poor or intermediate risk
disease (three out of six compared to 10 out of 36; P¼0.35).
However, the patients who suffered treatment-related deaths were
significantly more likely to have had cisplatin-refractory or
absolutely refractory disease (five out of six compared to 12 out
of 36; P¼0.03) and to fall into the poor risk prognostic category
(three out of six compared four out of 36; P¼0.04). In light of the
pulmonary toxicity of Carbop-EC-T, we wondered whether the
presence of lung metastases or the prior effects of bleomycin
increased the risk of developing pneumonitis. The incidence of
lung metastases was no greater in patients who suffered treatment-
related deaths than in the whole cohort, nor were there significant
differences in lung function. Both the median FEV1 (66%
predicted: range 47–87%) and KC0 (84% predicted; range 68–
100%) were lower than those of the whole cohort, but the
differences did not reach statistical significance.
We have previously treated 31 patients with relapsed or
refractory testicular GSTs with the Carbop-EC regime that lacks
paclitaxel but is otherwise the same as Carbop-EC-T (Lyttelton
et al, 1998). The previous cohort of patients did not differ
significantly from the current cohort in any of the characteristics
detailed in Table 1 (See supplementary Table 3), and the addition
of paclitaxel was not associated with any increase in nonpulmon-
ary toxicity (including the rate of neutrophil recovery, the
requirement for renal dialysis and the incidence of grade III/IV
mucositis). Intriguingly, the two patients who had previously
received Carbop-EC relapsing 12 and 24 months later and who
were then retreated with Carbop-EC-T are currently both alive and
well without relapse after 13 and 83 months, respectively. Taken
together, these data suggest that Carbop-EC-T can salvage previous
Carbop-EC chemotherapy failures and is probably no more toxic
than Carbop-EC when the paclitaxel is administered as three 24h
infusions.
DISCUSSION
Despite its widespread use, high-dose chemotherapy in the
management of testicular GCTs has remained controversial for
over a decade (Williams, 1992). The controversy has partially
arisen because there have been no published randomised trials that
compare high-dose and conventional dose treatments in relapsed
or poor risk disease. The multicentre IT-94 trial, performed under
the auspices of the European Group for Blood and Marrow
Transplantation, has completed recruitment and an interim
analysis has been presented in abstract form (Rosti et al, 2002).
A total of 280 patients who relapsed after first-line platinum-
containing chemotherapy were randomised either to four cycles of
VIP/VeIP (cisplatin, ifosfamide and either etoposide or vinblas-
tine) or three cycles of VIP/VeIP followed by high-dose Carbop-EC
(carboplatin 1–2.2gm
 2 adjusted according to EDTA clearance,
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Figure 3 Estimates of event-free (A) and overall (B) survival for patients
stratified according to the testicular GCT high-dose chemotherapy
prognostic scoring system. Score 0, good prognosis; score 1–2,
intermediate prognosis; score 42, poor prognosis.
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letoposide 1.8gm
 2, cyclophosphamide 6.4gm
 2). Of note, the
study population differed in two respects from that presented here.
Firstly, the IT-94 trial excluded patients classified as cisplatin
refractory or absolutely refractory. Secondly, 23 patients with
primary retroperitoneal disease and 24 with primary mediastinal
disease were enrolled. At a median follow-up of 41 months, there
was no difference between the study arms for 1-year event-free
survival (approximately 50%) and the 3-year overall survival
(53%). These results suggest that this nonpaclitaxel-containing
type of high-dose schedule given to a population with cisplatin-
sensitive disease is no better than standard-dose chemotherapy.
The mature results of the IT-94 study have not yet been subjected
to formal peer-review, but will be awaited with interest.
Direct comparisons between nonrandomised studies are illus-
trative, but fraught with difficulty, as there are inevitable
differences in treatment regimes and patient parameters, especially
in the extent of treatment prior to high-dose therapy. The first
report of a large cohort was published in 1989 (Nichols et al, 1989),
in which 33 heavily pretreated patients received etoposide
(1200mgm
 2) and carboplatin (900–1200mgm
 2). Two-thirds
of the patients had cisplatin-refractory disease and the treatment-
related mortality was 21%. However, despite these adverse
features, 44% of patients had objective responses and 10%
survived over 1 year. Since then, there has been refinement both
in terms of patient selection and supportive care. The largest
single-centre study reported on 150 patients (Rick et al, 1998)
treated with carboplatin (1500–2000mgm
 2), etoposide (1200–
2400mgm
 2) and ifosfamide (up to 10gm
 2). In the final analysis
of this cohort, two-thirds of patients had cisplatin-sensitive disease
and over 60% fell into the good prognostic risk (score 0) group.
Two-thirds of those treated received high-dose therapy as
intensification of first salvage treatment and the median event-
free and overall survivals were approximately 4 and 16 months,
respectively. The predicted long-term event-free and overall
survivals were 29 and 39%, respectively. Such figures have largely
been reproduced by other groups (Siegert et al, 1994; Flechon et al,
1999; Nichols and Maziarz, 1999), including our own (Lyttelton
et al, 1998). Where patients received high-dose chemotherapy
exclusively as part of first salvage treatment, survival figures are
improved, with nearly 60% of patients alive at a median follow-up
of 39 months (Bhatia et al, 2000). However, interpretation of these
last data is complicated by the fact that all patients received
tandem high-dose therapy and 10 of the 65 patients were treated as
part of a gene therapy protocol, with haematopoietic rescue
consisting of ex vivo cytokine-stimulated, mdr-1-transduced
CD34
þ cells. Of 65 patients, 25, including the 10 gene therapy
patients, also received maintenance oral etoposide.
In the absence of published randomised trial evidence, there has
been one attempt to compare conventional and high-dose first
salvage treatments in a matched pair analysis from two large
patient databases (Beyer et al, 2002). The criteria were patients
with proven relapsed NSGCT following first line cisplatin-based
treatment who were then treated with cisplatin-based salvage
treatment either with or without high-dose chemotherapy. In
analyses of both overall and event-free survivals, there was a
hazard ratio in statistically significant favour of high-dose
treatment. However, at 2 years, the estimated absolute benefit in
favour of high-dose chemotherapy was 6–12% for event-free
survival and 9–11% for overall survival, which was smaller than
was predicted from the single-centre phase I/II data.
Despite its activity in relapsed GCTs (Hinton et al, 2002; Motzer
et al, 2000b), there have been no previous reports of high-dose
chemotherapy that contains paclitaxel. There have been at least
two reports of its use in the conditioning regime prior to high-dose
therapy. In the first of these reports (Motzer et al, 2000a), two
doses of paclitaxel (200mgm
 2) and ifosfamide (6gm
 2) followed
by leukapheresis and three subsequent cycles of carboplatin (AUC
12–32) and etoposide (1200mgm
 2) with PBSC support were
administered to 37 patients with cisplatin-resistant GCTs. Over
60% patients responded with 40% of these responses proving
durable. In the second, 62 patients with relapsed or cisplatin-
resistant GCTs received three cycles of paclitaxel (175mgm
 2),
ifosfamide (6gm
 2) and cisplatin (100mgm
 2) followed by high-
dose carboplatin (1500mgm
 2), etoposide (2400mgm
 2) and
thiotepa (450–750mgm
 2) (Rick et al, 2001). In all, 66% of
patients responded and, at 3 years follow-up, there was a 30%
probability of overall survival and 25% probability of event-free
survival.
When compared to these previous studies, the results presented
here do suggest that the addition of paclitaxel to the high-dose
regime can improve both event-free and overall survival. In a
cohort in which the majority of patients had relapsed on more than
one occasion and had received a median of three previous
cisplatin-containing chemotherapy regimes, we estimate that, at 12
months, the probability of event-free survival is 51% and the
probability of overall survival is high at 67%. At 2 years, these
figures are 48 and 58%, respectively. To support further the notion
that the addition of paclitaxel to high-dose therapy might improve
the survival of poor risk GCT patients, we compared these results
with our previously published series of patients who had received
Carbop-EC alone. We appreciate that this is a retrospective
analysis and not a randomised prospective trial and so chance and/
or minor differences in patient prognostic variables could clearly
have a major impact upon the results, but we believe that this
comparison is meaningful since the two cohorts have been treated
at the same centres and have very similar characteristics.
Strikingly, this comparison revealed that the addition of paclitaxel
to Carbop-EC generates a statistically significant improvement in
event-free survival and may also improve overall survival (see
supplementary Figure 1).
After treating 23 patients with Carbop-EC-T in which the
paclitaxel was administered over 3h, there had been five
treatment-related deaths (22%), which compared to 3% in our
previous series and 6% in the IT-94 trial. The majority of the
deaths had been marked by pneumonitis. Taxane-induced
pneumonitis was first described in 1995 (Goldberg and Vannice,
1995) and there have been many subsequent confirmatory reports,
including in high-dose chemotherapy regimes (Khan et al, 1997;
Prince et al, 2000). However, the cause remains uncertain,
although postulated mechanisms have included delayed-type
hypersensitivity and massive cytokine release (Fujimori et al,
1998). In patients with lung or breast cancers, previous irradiation
may play a role (Khan et al, 1997), while the previous
administration of bleomycin might potentially be relevant in our
series. In the majority of reported cases, the taxanes were
administered over 3h. The responsiveness of the pneumonitis to
corticosteroids varies greatly in published reports (Khan et al,
1997; Prince et al, 2000). However, there appears to be some
evidence that the incidence of paclitaxel-induced pneumonitis can
be reduced both by steroid prophylaxis (Thomas et al, 2000) and
prolonged infusion of the drug (Zimmerman et al, 1998). Thus, we
treated the subsequent 13 patients with prednisolone prophylaxis
(30mg b.d. for 14 days starting on day 0) and gave the paclitaxel as
three 24h infusions. We have also used this regime to treat two
patients with relapsed ovarian GCTs and three patients with
relapsed gestational choriocarcinoma. Only one of these 18
patients has suffered a treatment-related death (5.5%) suggesting
that this altered Carbop-EC-T regime has reduced toxicity. Further
patients will now need to be treated to confirm this.
Previous reports (Beyer et al, 1996; Lyttelton et al, 1998),
including our current data, have shown that patients with
cisplatin-refractory disease have significantly poorer outcomes
than those who are cisplatin sensitive. However, it is noticeable
that two patients presented here with cisplatin-refractory disease
have survived long term (over 44 months), one of whom was
absolutely refractory. Nevertheless, when patients are analysed
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poor risk group have a uniformly poor outcome as well as a very
high probability of suffering a treatment-related death. Thus, we
believe that careful consideration should be given to the
appropriateness of administering high-dose therapy to those with
the poorest prognosis.
In summary, we have described a paclitaxel-containing high-
dose chemotherapy regime for relapsed or refractory GCTs that
may significantly improve the survival rates in this disease when
compared to other high-dose regimes. We believe that the extra
toxicity of this regime can be minimised with combined steroid
prophylaxis and prolonged paclitaxel infusion. Although these
favourable results may simply reflect chance, we suggest that a
paclitaxel-containing regime should be considered in any future
randomised trial of high-dose chemotherapy in GCTs.
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